A J Breugom1, E Bastiaannet2, P G Boelens1, L H Iversen3, A Martling4, R Johansson5, T Evans6, S Lawton7, K M O'Brien8, E Van Eycken9, R Janciauskiene10, G J Liefers1, A Cervantes11, V E P P Lemmens12, C J H van de Velde13. 1. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. 2. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands. 3. Department of Surgery, Aarhus University Hospital, Aarhus, Denmark. 4. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 5. Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden. 6. Public Health England, Birmingham, United Kingdom. 7. Public Health England, York, United Kingdom. 8. National Cancer Registry Ireland, Cork, Ireland. 9. Belgian Cancer Registry, Brussels, Belgium. 10. Oncology Institute of Lithuanian University of Health Sciences, Kaunas, Lithuania. 11. Department of Haematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain. 12. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Eindhoven, The Netherlands; Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands. 13. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: C.J.H.van_de_Velde@lumc.nl.
Abstract
BACKGROUND: The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries. METHODS: Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries. RESULTS: Overall, 59,154 patients were included. The proportion of patients receiving adjuvant chemotherapy ranged from 7.1% to 29.0% (p < 0.001). Compared with NL, a better adjusted relative survival was observed in SE (stage II: relative excess risks (RER) 0.53, 95% confidence interval (CI) 0.44-0.64; p < 0.001), and BE (stage II: RER 0.84, 95% CI 0.76-0.92; p < 0.001), and in IE for patients with stage IIA disease (RER 0.80, 95% CI 0.65-0.98; p = 0.03). CONCLUSION: The proportion of patients with stage II colon cancer receiving adjuvant chemotherapy varied largely between seven European countries. No clear linear pattern between adjuvant chemotherapy and adjusted relative survival was observed. Compared with NL, SE and BE showed an improved adjusted relative survival for stage II disease, and IE for patients with stage IIA disease only. Further research into selection criteria for adjuvant chemotherapy could eventually lead to individually tailored, optimal treatment of patients with stage II colon cancer.
BACKGROUND: The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries. METHODS: Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries. RESULTS: Overall, 59,154 patients were included. The proportion of patients receiving adjuvant chemotherapy ranged from 7.1% to 29.0% (p < 0.001). Compared with NL, a better adjusted relative survival was observed in SE (stage II: relative excess risks (RER) 0.53, 95% confidence interval (CI) 0.44-0.64; p < 0.001), and BE (stage II: RER 0.84, 95% CI 0.76-0.92; p < 0.001), and in IE for patients with stage IIA disease (RER 0.80, 95% CI 0.65-0.98; p = 0.03). CONCLUSION: The proportion of patients with stage II colon cancer receiving adjuvant chemotherapy varied largely between seven European countries. No clear linear pattern between adjuvant chemotherapy and adjusted relative survival was observed. Compared with NL, SE and BE showed an improved adjusted relative survival for stage II disease, and IE for patients with stage IIA disease only. Further research into selection criteria for adjuvant chemotherapy could eventually lead to individually tailored, optimal treatment of patients with stage II colon cancer.
Authors: Nina C A Vermeer; Yvette H M Claassen; Marloes G M Derks; Lene H Iversen; Elizabeth van Eycken; Marianne G Guren; Pawel Mroczkowski; Anna Martling; Robert Johansson; Tamara Vandendael; Arne Wibe; Bjorn Moller; Hans Lippert; Johanneke E A Portielje; Gerrit Jan Liefers; Koen C M J Peeters; Cornelis J H van de Velde; Esther Bastiaannet Journal: Oncologist Date: 2018-03-22
Authors: Jung Rae Cho; Keun-Wook Lee; Heung-Kwon Oh; Jin Won Kim; Ji-Won Kim; Duck-Woo Kim; Jee Hyun Kim; Sung-Bum Kang Journal: Ann Surg Treat Res Date: 2022-05-03 Impact factor: 1.766
Authors: Masoud Babaei; Yesilda Balavarca; Lina Jansen; Valery Lemmens; Felice N van Erning; Liesbet van Eycken; Evelien Vaes; Annika Sjövall; Bengt Glimelius; Cornelia M Ulrich; Petra Schrotz-King; Hermann Brenner Journal: Int J Cancer Date: 2017-12-04 Impact factor: 7.396
Authors: Y H M Claassen; E Bastiaannet; H H Hartgrink; J L Dikken; W O de Steur; M Slingerland; R H A Verhoeven; E van Eycken; H de Schutter; M Lindblad; J Hedberg; E Johnson; G O Hjortland; L S Jensen; H J Larsson; T Koessler; M Chevallay; W H Allum; C J H van de Velde Journal: BJS Open Date: 2018-10-09
Authors: Min Ki Kim; Daeyoun David Won; Sun Min Park; Taejung Kim; Sung Ryong Kim; Seong Taek Oh; Seung Kook Sohn; Mi Yeon Kang; In Kyu Lee Journal: Cancer Res Treat Date: 2017-12-07 Impact factor: 4.679